OncoMatch/Clinical Trials/NCT06230445
Effects of Digital Therapeutic in Whole Process Management of Lung Cancer
Is NCT06230445 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for application of digital therapeutic in lung cancer whole process management.
This trial will randomize patients into two groups, the treatment group will use the digital therapeutic application named 'UHealth' for the whole process management and the control group will use regular follow-up. The trial aims to look into the difference between quality of life, anxiety/depression index, emergency treatment times, hospital admission rate, treatment compliance, OS, DFS and follow-up cost.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery
Patients have received surgery
Must have received: neoadjuvant therapy
Patients have received ... neoadjuvant therapy
Must have received: adjuvant therapy
Patients have received ... adjuvant therapy
Must have received: radiation therapy
Patients have received ... radiotherapy
Must have received: cytotoxic chemotherapy
Patients have received ... cytotoxic chemotherapy
Must have received: targeted therapy
Patients have received ... targeted therapy
Must have received: immunotherapy
Patients have received ... immunotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify